Nivolumab biosimilar(ISU Abxis)

纳武利尤单抗生物类似药（ISU Abxis）

Report date: 2025/02/18 11:33:18

Base Information

Drug NameNivolumab biosimilar(ISU Abxis)
Drug Alias NameISU-106
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesIsu Abxis Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIsu Abxis Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A